Cargando…

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

BACKGROUND: Infliximab was the first approved biologic treatment for moderate to severe Crohn’s disease (MS-CD) in China. However, the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD relative to conventional maintenance therapy remained unclarified. AIM: To assess the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Ji-Hao, Luo, Liang, Chen, Xiao-Li, Pan, Yi-Peng, Zhang, Zhou, Fang, Hao, Chen, Ying, Chen, Wen-Dong, Cao, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656205/ https://www.ncbi.nlm.nih.gov/pubmed/33244205 http://dx.doi.org/10.3748/wjg.v26.i41.6455

Ejemplares similares

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
por: Zaltman, Cyrla, et al.
Publicado: (2021)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Etiology analysis for term newborns with severe hyperbilirubinemia in eastern Guangdong of China
por: Xu, Jia-Xin, et al.
Publicado: (2023)

Family history and disease outcomes in patients with Crohn’s disease: A comparison between China and the United States
por: Wang, Pei-Qi, et al.
Publicado: (2016)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease
por: Luo, Youyou, et al.
Publicado: (2017)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease
por: Sun, Chen-Ming, et al.
Publicado: (2017)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas
por: Wu, Xiao-Li, et al.
Publicado: (2016)

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China
por: Zhang, Tianyu, et al.
Publicado: (2016)

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Fungal dysbiosis predicts the diagnosis of pediatric Crohn’s disease
por: El Mouzan, Mohammad I, et al.
Publicado: (2018)

Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes
por: Stapff, Manfred Paul
Publicado: (2018)

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study
por: Lv, Xin-Yue, et al.
Publicado: (2020)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease
por: Gupta, Neera, et al.
Publicado: (2018)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Acute gastrointestinal injury in critically ill patients with COVID-19 in Wuhan, China
por: Sun, Jia-Kui, et al.
Publicado: (2020)

Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort
por: Schnitzler, Fabian, et al.
Publicado: (2021)

Low-radiation and high image quality coronary computed tomography angiography in “real-world” unselected patients
por: Richards, Caryl Elizabeth, et al.
Publicado: (2018)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study
por: González-Montero, Jaime, et al.
Publicado: (2023)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Temporal trends in the misdiagnosis rates between Crohn’s disease and intestinal tuberculosis
por: Seo, Hyungil, et al.
Publicado: (2017)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
por: Ramos, Huascar, et al.
Publicado: (2017)

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
por: Abrignani, Maurizio Giuseppe, et al.
Publicado: (2022)

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe
por: Huynh, Lynn, et al.
Publicado: (2022)

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)

Simple pain measures reveal psycho-social pathology in patients with Crohn’s disease
por: Odes, Shmuel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7pkvn3ao0h2hgcaredijjvn66t